Like any other rare disease, one issue that hinders interpretation of the pathogenicity of LZTR1 variants detected in clinical laboratories is there are so few schwannomatosis cases, leading to an insufficient level of evidence. This evidence concerns the gene LZTR1 and schwannomatosis.